Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-dose Aprepitant for PONV in Bariatric Surgery
NCT05189756Phase 4Terminated
- Sponsor
- Insel Gruppe
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aprepitant in postoperative nausea and vomiting (PONV), sponsored by Insel Gruppe. Started Mar 2022; status: terminated.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT05189756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189756.